通过不可逆转的SRC家族激酶抑制剂选择性向不同的活性位点核友
Nathan N Gushwa1, Sumin Kang, Jing Chen
1Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94158, United States.
Journal of the American Chemical Society
|November 30, 2012
概括
新的化学探测器精确地准活细胞中的Src家族激酶. 这些工具有助于了解药物选择性,并确定哪些激酶受到波纳替尼布等治疗的影响.
科学领域:
- 生物化学 生物化学
- 化学生物学 化学生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- Src-家族激酶对人类健康和疾病至关重要.
- 针对这些激酶的现有药物缺乏选择性.
- 在活细胞中评估激酶选择性是具有挑战性的.
研究的目的:
- 设计和验证Src家族激酶的新型化学探针.
- 为了实现细胞内内源性激酶的选择性标记和分析.
- 调查药物波纳替尼对Src家族激酶的选择性.
主要方法:
- 开发了两种基于核酸的化学探针 (1和2),配有基标签.
- 探测器1的目标是保存的氨酸;探测器2的目标是可变的氨酸.
- 使用探针在完整细胞中竞争性分析激酶抑制剂.
主要成果:
- 两个探测器都有效地标记了它们在细胞中预期的内源性激酶点.
- 探头1显示出广泛的反应性,而探头2显示出对特定激酶的选择性.
- 波纳替尼可选择性抑制T细胞激酶Lck,对Fyn或Src的影响最小.
结论:
- 开发的化学探针可以精确地分析 Src 类基因酶在生物系统中的特征.
- 这些探针有助于评估药物选择性与不同的激酶子集的对比.
- 结果揭示了ponatinib在Src家族中的Lck的特定抑制作用.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...

